Cargando…

Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy

We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice and successfully proved TSP-2 overexpression as a therapeutic concept in a short term glomerulonephritis model in the rat. In this current stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Christoph, Vogelbacher, Regina, Stief, Andrea, Grigo, Christina, Hugo, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871554/
https://www.ncbi.nlm.nih.gov/pubmed/24376766
http://dx.doi.org/10.1371/journal.pone.0083846
_version_ 1782296833668677632
author Daniel, Christoph
Vogelbacher, Regina
Stief, Andrea
Grigo, Christina
Hugo, Christian
author_facet Daniel, Christoph
Vogelbacher, Regina
Stief, Andrea
Grigo, Christina
Hugo, Christian
author_sort Daniel, Christoph
collection PubMed
description We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice and successfully proved TSP-2 overexpression as a therapeutic concept in a short term glomerulonephritis model in the rat. In this current study, we investigated if long-term TSP-2 overexpression is also capable to ameliorate the progression of chronic kidney disease in the setting of the chronic allograft nephropathy F344-Lewis model in the rat. Two weeks after renal transplantation, two rat thigh muscles were transfected once only with either a TSP-2 overexpressing plasmid (n = 8) or a luciferase-expressing plasmid as control (n = 8). Rats were monitored for renal function, histological changes and gene expression in the graft for up to 30 weeks after transplantation. Unexpectedly, only in the TSP-2 treated group 2 rats died before the end of the experiment and renal function tended to be worsened in the TSP-2 group compared to the luciferase-treated controls. In addition, glomerular sclerosis and tubular interstitial injury as well as cortical fibronectin deposition was significantly increased in the TSP-2 treated kidneys despite reduced TGF-β activation and marked anti-inflammatory (macrophages, T-cells and B-cells) effects in this group. Long-term TSP-2 therapy impaired repair of renal endothelium, as demonstrated by significant higher glomerular and peritubular endothelial rarefaction and reduced endothelial cell proliferation in the transplanted kidneys from TSP-2 treated rats compared to controls. This TSP-2 effect was associated with decreased levels of renal VEGF but not VEGF1 receptor. In conclusion, despite its anti-inflammatory and TGF-β activation blocking effects, TSP-2 gene therapy did not ameliorate but rather worsened experimental chronic allograft nephropathy most likely via its anti-angiogenic properties on the renal microvasculature.
format Online
Article
Text
id pubmed-3871554
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38715542013-12-27 Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy Daniel, Christoph Vogelbacher, Regina Stief, Andrea Grigo, Christina Hugo, Christian PLoS One Research Article We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice and successfully proved TSP-2 overexpression as a therapeutic concept in a short term glomerulonephritis model in the rat. In this current study, we investigated if long-term TSP-2 overexpression is also capable to ameliorate the progression of chronic kidney disease in the setting of the chronic allograft nephropathy F344-Lewis model in the rat. Two weeks after renal transplantation, two rat thigh muscles were transfected once only with either a TSP-2 overexpressing plasmid (n = 8) or a luciferase-expressing plasmid as control (n = 8). Rats were monitored for renal function, histological changes and gene expression in the graft for up to 30 weeks after transplantation. Unexpectedly, only in the TSP-2 treated group 2 rats died before the end of the experiment and renal function tended to be worsened in the TSP-2 group compared to the luciferase-treated controls. In addition, glomerular sclerosis and tubular interstitial injury as well as cortical fibronectin deposition was significantly increased in the TSP-2 treated kidneys despite reduced TGF-β activation and marked anti-inflammatory (macrophages, T-cells and B-cells) effects in this group. Long-term TSP-2 therapy impaired repair of renal endothelium, as demonstrated by significant higher glomerular and peritubular endothelial rarefaction and reduced endothelial cell proliferation in the transplanted kidneys from TSP-2 treated rats compared to controls. This TSP-2 effect was associated with decreased levels of renal VEGF but not VEGF1 receptor. In conclusion, despite its anti-inflammatory and TGF-β activation blocking effects, TSP-2 gene therapy did not ameliorate but rather worsened experimental chronic allograft nephropathy most likely via its anti-angiogenic properties on the renal microvasculature. Public Library of Science 2013-12-23 /pmc/articles/PMC3871554/ /pubmed/24376766 http://dx.doi.org/10.1371/journal.pone.0083846 Text en © 2013 Daniel et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Daniel, Christoph
Vogelbacher, Regina
Stief, Andrea
Grigo, Christina
Hugo, Christian
Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy
title Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy
title_full Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy
title_fullStr Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy
title_full_unstemmed Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy
title_short Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy
title_sort long-term gene therapy with thrombospondin 2 inhibits tgf-β activation, inflammation and angiogenesis in chronic allograft nephropathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871554/
https://www.ncbi.nlm.nih.gov/pubmed/24376766
http://dx.doi.org/10.1371/journal.pone.0083846
work_keys_str_mv AT danielchristoph longtermgenetherapywiththrombospondin2inhibitstgfbactivationinflammationandangiogenesisinchronicallograftnephropathy
AT vogelbacherregina longtermgenetherapywiththrombospondin2inhibitstgfbactivationinflammationandangiogenesisinchronicallograftnephropathy
AT stiefandrea longtermgenetherapywiththrombospondin2inhibitstgfbactivationinflammationandangiogenesisinchronicallograftnephropathy
AT grigochristina longtermgenetherapywiththrombospondin2inhibitstgfbactivationinflammationandangiogenesisinchronicallograftnephropathy
AT hugochristian longtermgenetherapywiththrombospondin2inhibitstgfbactivationinflammationandangiogenesisinchronicallograftnephropathy